Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Summary

The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.

Timeline

Start

2025-01-02

Primary completion

2026-01-22

Completion

2026-01-22

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications